צמיחת מכירות משנה לשנה (TTM): Park Ha Biological Technology Company Limited (PHH)

Hemp extract products are driving current growth for Park Ha Biological Technology (PHH) in China, with regulatory risks already priced in. However, raw material volatility and fierce competition are squeezing margins. Business flexibility is maintained through the outsourcing of production and logistics. The last twelve months (LTM) change in trading revenue illustrates the revenue trend, where the value serves as the baseline indicator of the current trend.
Park Ha Biological Technology - פילוחים אנליטיים ומדדי מפתח (PHH)

Park Ha Biological Technology (PHH) is currently adapting its pricing policy to account for declining consumer spending. Analyzing the year-over-year revenue dynamics over a 12-month period allows investors to gauge the effectiveness of this transformation. This metric calculates the rolling annual revenue growth, measuring the real-time expansion rate of the business. The positive trend confirms a successful capture of the budget-friendly alternatives market. However, sales growth without controlling the debt load could create risks for capital stability.